Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
A slew of new medicines will be added to Japan’s NHI price list on September 4, with a key reimbursement policy panel giving them the thumbs-up on August 28 including Roche/Chugai Pharmaceutical’s tumor-agnostic agent Rozlytrek (entrectinib) and Alnylam Pharmaceuticals’ Onpattro…
To read the full story
Related Article
- 1st RNAi Therapy Onpattro Makes Japan Debut
September 10, 2019
- Roche/Chugai’s Rozlytrek, AstraZeneca COPD Combos and More Hit Shelves
September 5, 2019
- Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
August 29, 2019
REGULATORY
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
- LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…